What Nuvectis Pharma does

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for complement-mediated diseases and oncology. Founded around 2020-2021 and headquartered in Fort Lee, New Jersey, the company is publicly traded on NASDAQ under the ticker NVCT and operates with a team of 11-50 employees. Nuvectis has no commercialized products and generates no product revenue, relying instead on equity financing and licensing arrangements to fund operations.

The company's pipeline consists of four oral small-molecule drug candidates, each with a differentiated mechanism of action. NXP900 is a Type 1.5 SRC Family Kinase inhibitor that achieves complete shutdown of SRC signaling by inhibiting both catalytic and scaffolding functions, currently advancing through Phase 1b trials in advanced solid tumors and showing preclinical synergy with sotorasib in NSCLC models. NXP800 is a GCN2 activator licensed from the CRT Pioneer Fund, evaluated for platinum-resistant ARID1a-mutated ovarian cancer and cholangiocarcinoma. In June 2026, Nuvectis significantly expanded its pipeline through a licensing deal with Haisco Pharmaceutical Group, adding NXP100 (a Complement Factor B inhibitor for PNH, IgAN, lupus nephritis, and other complement-mediated conditions) and NXP200 (a paradox-breaker BRAF inhibitor for Class I/II/III BRAF-mutated malignancies).

Nuvectis's business model centers on licensing intellectual property from research institutions and pharmaceutical partners, advancing candidates through clinical trials, and ultimately monetizing through milestone payments, royalties, or potential commercialization partnerships. The company has raised approximately $61.7 million cumulatively across private placements (October 2021, July 2022), a Series A (June 2024), and a post-IPO public offering (February 2025). The June 2026 Haisco agreement is the largest commercial transaction in the company's history, with up to $40 million in upfront and near-term payments plus up to $1.421 billion in potential milestones and tiered royalties. Patient segments addressed include those suffering from complement-mediated rare and orphan diseases and from hard-to-treat solid tumors including EGFR-mutated NSCLC, ARID1a-mutated ovarian cancer, cholangiocarcinoma, and BRAF-mutated malignancies.

Name

Nuvectis Pharma

Legal name

Nuvectis Pharma, Inc.

Website

https://nuvectis.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing four oral small-molecule drug candidates for complement-mediated diseases and oncology. The publicly traded firm (NASDAQ: NVCT) licenses precision medicines from Haisco and CRT Pioneer Fund and has no commercialized products.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals (Precision Oncology and Complement Therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Precision oncology medicines
• Kinase inhibitor drugs
• Complement pathway therapeutics
• Biopharmaceutical drug development
• Cancer therapeutics pipeline

Headquarters

HQ city

Fort Lee

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and Milestone Payments: As a clinical-stage biopharmaceutical company, Nuvectis generates revenue through licensing agreements that include upfront payments, development/regulatory/commercial milestone payments, and tiered royalties on net sales of approved products. The company has no commercialized products and is not yet profitable.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for the treatment of oncology and complement-related diseases. Its pipeline includes four drug candidates: NXP900 (SRC Family Kinase inhibitor), NXP800 (GCN2 kinase activator), NXP100 (Complement Factor B inhibitor), and NXP200 (paradox-breaker BRAF inhibitor), all in-licensed from research and pharmaceutical partners and advanced through clinical trials toward regulatory approval.

Product overview

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing a portfolio of precision medicines for complement-related conditions and oncology. The company's pipeline includes four drug candidates: NXP900 (SRC/YES1 kinase inhibitor for solid tumors), NXP800 (GCN2 kinase activator for ovarian cancer and cholangiocarcinoma), NXP100 (Complement Factor B inhibitor for complement-mediated diseases including PNH and IgAN), and NXP200 (paradox-breaker BRAF inhibitor for BRAF-mutated malignancies).

Differentiator

Problem solved

Functional benefit

Products and services

• NXP900 Oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1, with a Type 1.5 mechanism of action that inhibits both catalytic and scaffolding functions of SRC kinase for complete signaling pathway shutdown. Completed dose escalation in advanced solid tumors and a drug-drug interaction study; in Phase 1b program as single agent and in combination with other anti-cancer agents.
• NXP800 Oral small molecule activator of the kinase GCN2, evaluated for the treatment of platinum-resistant ARID1a-mutated ovarian cancer and cholangiocarcinoma (with an investigator-sponsored trial led by Mayo Clinic). Demonstrated biologic activity in Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer.
• NXP100 Oral, once-daily small molecule inhibitor of Complement Factor B, a critical protease within the alternative pathway of the complement cascade. Halts formation and stabilization of the C3 convertase and its positive feedback amplification loop. In development for paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN), lupus nephritis, C3 glomerulonephritis, myasthenia gravis, and dry age-related macular degeneration. Phase 3 data demonstrated efficacy superior to C5 inhibitors like Soliris in PNH.
• NXP200 Oral small-molecule paradox-breaker BRAF inhibitor that circumvents paradoxical activation caused by first-generation BRAF inhibitors by physically disrupting BRAF dimer formation. Targets Class I, Class II, and Class III BRAF mutations across multiple tumor types.

Quantifiable outcome

• NXP100 showed Phase 3 efficacy superior to C5 inhibitors like Soliris in PNH treatment
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Haisco Pharmaceutical GroupcoreStrategic or Co-development Partner · 22 June 2026Nuvectis entered into a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds: NXP100 (Complement Factor B inhibitor) and NXP200 (BRAF inhibitor). Haisco will receive up to $40 million in upfront and near-term payments, with potential milestone payments up to $1.421 billion plus tiered royalties on net sales. This deal transforms Nuvectis into a late-stage clinical development company.
• CRT Pioneer FundcoreOEM/ Whitelabel/ Licensing Partner · 4 June 2024Nuvectis licensed exclusive rights to develop NXP800, a novel cancer drug candidate, from the CRT Pioneer Fund. The company aims to advance NXP800 through clinical trials targeting hard-to-treat solid tumors, building on research from the Institute for Cancer Research UK.
• Institute for Cancer Research UKminorStrategic or Co-development PartnerResearch foundation whose work underlies the NXP800 drug candidate licensed from CRT Pioneer Fund. Nuvectis builds on research from this institute for cancer drug development.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Apellis Pharmaceuticals: Clinical-stage biopharma developing complement inhibitors including Empaveli (pegcetacoplan) for PNH, directly competing with Nuvectis's NXP100 in the same indication via a different pathway (C3 vs Factor B).
• Revolution Medicines: Clinical-stage precision oncology company developing targeted small molecule inhibitors for difficult-to-treat solid tumors, comparable in stage, approach, and target patient population to Nuvectis's NXP900 and NXP800 programs.
• Black Diamond Therapeutics: Precision oncology company developing next-generation kinase inhibitors including BRAF-targeted therapies, directly comparable to Nuvectis's NXP200 paradox-breaker BRAF inhibitor program.
• Relay Therapeutics: Clinical-stage precision oncology company using structure-based drug design to develop targeted therapies for solid tumors, comparable in stage and precision-medicine approach to Nuvectis.
• Erasca: Clinical-stage precision oncology company developing kinase inhibitors for RAS/MAPK pathway-driven cancers, directly comparable in mechanism and target patient population to Nuvectis's kinase inhibitor programs.
• Crinetics Pharmaceuticals: Clinical-stage biopharma developing targeted oral small molecule therapies for rare endocrine diseases, comparable in company stage, oral small molecule approach, and rare-disease focus to Nuvectis.
• Arvinas: Clinical-stage precision oncology company developing novel targeted protein degraders, comparable in clinical stage and precision medicine approach targeting difficult oncology indications like Nuvectis.
• Omeros Corporation: Clinical-stage biopharma with complement inhibitor programs including narsoplimab for IgA nephropathy and other complement-mediated diseases, directly comparable to Nuvectis's NXP100 indication set.

Broad incumbents

• Alexion (AstraZeneca Rare Disease): Established leader in PNH and complement-mediated diseases with Soliris and Ultomiris (C5 inhibitors), represents the entrenched competitor that NXP100 aims to disrupt with oral Factor B inhibition.
• BridgeBio Pharma: Larger clinical-stage biopharma developing targeted therapies for rare genetic diseases, comparable in precision-medicine philosophy and rare-disease focus to Nuvectis's complement pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nuvectis-pharma-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuvectis Pharma